JP4297207B2 - 止血障害処置のための治療組成物に使用するためのリガンド - Google Patents

止血障害処置のための治療組成物に使用するためのリガンド Download PDF

Info

Publication number
JP4297207B2
JP4297207B2 JP2001509473A JP2001509473A JP4297207B2 JP 4297207 B2 JP4297207 B2 JP 4297207B2 JP 2001509473 A JP2001509473 A JP 2001509473A JP 2001509473 A JP2001509473 A JP 2001509473A JP 4297207 B2 JP4297207 B2 JP 4297207B2
Authority
JP
Japan
Prior art keywords
factor viii
factor
monoclonal antibody
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001509473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003504045A5 (cg-RX-API-DMAC7.html
JP2003504045A (ja
Inventor
ジャックマン，マール・ジィ
サン−レミィ，ジャン−マリー・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Sciences Research Partners
Original Assignee
Life Sciences Research Partners
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916450.1A external-priority patent/GB9916450D0/en
Application filed by Life Sciences Research Partners filed Critical Life Sciences Research Partners
Publication of JP2003504045A publication Critical patent/JP2003504045A/ja
Publication of JP2003504045A5 publication Critical patent/JP2003504045A5/ja
Application granted granted Critical
Publication of JP4297207B2 publication Critical patent/JP4297207B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2001509473A 1999-07-14 2000-07-13 止血障害処置のための治療組成物に使用するためのリガンド Expired - Fee Related JP4297207B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14389199P 1999-07-14 1999-07-14
US60/143,891 1999-07-14
GBGB9916450.1A GB9916450D0 (en) 1999-07-14 1999-07-14 Ligands for use in therapeutic compounds for the treatment of hemostasis disorders
GB9916450.1 1999-07-14
PCT/EP2000/006677 WO2001004269A1 (en) 1999-07-14 2000-07-13 Ligands for use in therapeutic compositions for the treatment of hemostasis disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008198354A Division JP4297225B2 (ja) 1999-07-14 2008-07-31 止血障害処置のための治療組成物に使用するためのリガンド

Publications (3)

Publication Number Publication Date
JP2003504045A JP2003504045A (ja) 2003-02-04
JP2003504045A5 JP2003504045A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4297207B2 true JP4297207B2 (ja) 2009-07-15

Family

ID=26315767

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001509473A Expired - Fee Related JP4297207B2 (ja) 1999-07-14 2000-07-13 止血障害処置のための治療組成物に使用するためのリガンド
JP2008198354A Expired - Fee Related JP4297225B2 (ja) 1999-07-14 2008-07-31 止血障害処置のための治療組成物に使用するためのリガンド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008198354A Expired - Fee Related JP4297225B2 (ja) 1999-07-14 2008-07-31 止血障害処置のための治療組成物に使用するためのリガンド

Country Status (11)

Country Link
EP (1) EP1194528B1 (cg-RX-API-DMAC7.html)
JP (2) JP4297207B2 (cg-RX-API-DMAC7.html)
AT (1) ATE356201T1 (cg-RX-API-DMAC7.html)
AU (1) AU781638B2 (cg-RX-API-DMAC7.html)
CA (1) CA2381125C (cg-RX-API-DMAC7.html)
CY (1) CY1107638T1 (cg-RX-API-DMAC7.html)
DE (1) DE60033814T2 (cg-RX-API-DMAC7.html)
DK (1) DK1194528T3 (cg-RX-API-DMAC7.html)
ES (1) ES2283308T3 (cg-RX-API-DMAC7.html)
PT (1) PT1194528E (cg-RX-API-DMAC7.html)
WO (1) WO2001004269A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
DK1222929T3 (da) 2001-01-11 2010-09-06 Life Sciences Res Partners Vzw Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
AU2002313194B9 (en) * 2001-06-12 2008-06-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor VIII antibody
EP1388544A1 (en) 2002-07-31 2004-02-11 D. Collen Research Foundation vzw Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
CA2535489C (en) 2003-08-14 2014-09-30 D. Collen Research Foundation Vzw Antibodies against factor viii with modified glycosylation in the variable region
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
ATE509957T1 (de) * 2005-07-29 2011-06-15 Life Sciences Res Partners Vzw An die a2-domäne bindende, humane inhibitorische anti-faktor-viii-antikörper
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
EP2785739B1 (en) 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
EP3426685A1 (en) 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
KR20200005635A (ko) * 2017-05-11 2020-01-15 브이아이비 브이지더블유 가변 면역글로불린 도메인의 글리코실화

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
ATE356201T1 (de) 2007-03-15
DK1194528T3 (da) 2007-07-09
CA2381125C (en) 2013-04-23
EP1194528A1 (en) 2002-04-10
DE60033814T2 (de) 2007-11-08
CY1107638T1 (el) 2013-04-18
AU6273000A (en) 2001-01-30
JP2003504045A (ja) 2003-02-04
JP4297225B2 (ja) 2009-07-15
CA2381125A1 (en) 2001-01-18
JP2008295455A (ja) 2008-12-11
AU781638B2 (en) 2005-06-02
EP1194528B1 (en) 2007-03-07
PT1194528E (pt) 2007-05-31
WO2001004269A1 (en) 2001-01-18
DE60033814D1 (de) 2007-04-19
ES2283308T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
JP4297225B2 (ja) 止血障害処置のための治療組成物に使用するためのリガンド
EP1007089B1 (en) Anticoagulant humanised antibodies against factor IX, for use in the treatment of thrombosis
JP2009528285A (ja) ファクターｖｉｉｉのｃ１ドメインに対する阻害抗体の阻害活性を中性化する抗イデオタイプ抗体
EP1282444B1 (en) Antithrombotic agents
AU2000278584A1 (en) Antithrombotic agents
US20030175268A1 (en) Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
US20020136725A1 (en) Antithrombotic agents
US7067313B1 (en) Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
EP1222929B1 (en) Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
US20030235587A1 (en) Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) Antithrombotic agents
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis
HK1109339A (en) Antithrombotic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080731

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20081015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090310

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090407

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120424

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130424

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140424

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees